Tariq SM, Thomas EC. Maintenance therapy in COPD: time to phase out ICS and switch to the new LAMA/LABA inhalers? Int J Chron Obstruct Pulmon Dis. 2017;12:1877-1882.Tariq SM, Thomas EC. Maintenance therapy in COPD: time to phase out ICS and switch to the new LAM...
The results are promising and favor the LAMA/LABA inhalers, especially in the longer duration trials. Furthermore, there is a clearer picture emerging as to the subgroup of COPD patients who may be able to successfully switch from their current ICS/LABA therapy to these new LAMA/LABA inhaler...
The LAMA glycopyrronium (GP) is an approved monotherapy for the maintenance treatment of COPD [15,16] and is available as a dry powder inhaler in Japan. GFF MDI (Bevespi Aerosphere®) is a fixed-dose combination (FDC) of GP (14.4 μg) and the LABA formoterol fumarate dihydrate (FF...
Inhaled bronchodilators including long-acting beta-agonist (LABA) and long-acting muscarinic antagonist (LAMA) play a central role in the treatment of stable chronic obstructive pulmonary disease (COPD). However, it is still unclear whether LABA or LAMA should be used for the initial treatment. ...
InhalersLABALAMAPharmacotherapyInhaled fixed-dose combinations (FDCs) of a long-acting 尾-agonist (LABA) and a long-acting muscarinic antagonist (LAMA) have become the cornerstone for the maintenance treatment of symptomatic COPD patients. In this regard, global COPD treatment guidelines have ...